Roivant Sciences Ltd
For the period ended Jun 30, 2024. Filed Aug 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 9, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
| Item 5. | Other Information. |
|---|
Rule 10b5-1 Trading Arrangements
During the three months ended June 30, 2024, the officer listed below adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
On June 25, 2024, Eric Venker, our President, Chief Operating Officer, entered into a trading plan that provides for the sale of up to 2,381,883 common shares underlying stock options to purchase common shares. The plan will expire on September 23, 2025, subject to early termination for certain specified events set forth in the plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.